Citations

Clear

71 citation(s) found for "Mini, GK".

Reply to: Comments on “Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database”
Achilli, Pietro , Crippa, Jacopo , Achilli, P , Grass, Fabian , Larson, David W.

Mayo Clinic

International Journal of Cancer | August 15, 2020 | Volume: 148 | Issue: 4 | Pages: 1028-1029

10.1002/ijc.33256 | PMID 33034382 Get It

Renal Survival in Children with Glomerulonephritis with Crescents: A Pediatric Nephrology Research Consortium Cohort Study
Maliakkal, Joseph , Hicks, John , Michael, Mini , Selewski, David T. , Twombley, Katherine , Rheault, Michelle N. , Seamon, Meredith, Misurac, Jason , Tran, Cheryl L. , Reyes, Loretta , Onder, Ali Mirza , Constantinescu, Alexandru R. , Singh, Vaishali , Pan, Cynthia G., Omoloja, Abiodun , Wu, Qiang , Smoyer, William E., Hidalgo, Guillermo , Wenderfer, Scott E. , Misurac, Jason M , Wenderfer, Scott E , Twombley, Katherine E , Flynn, Joseph T. , Smoyer, William E.

Mayo Clinic

Journal of Clinical Medicine | July 27, 2020 | Volume: 9 | Issue: 8 | Pages: 2385

10.3390/jcm9082385 | PMID 32722612 Get It

There is no evidence-based definition for diagnosing crescentic glomerulonephritis. The prognostic implications of crescentic lesions on kidney biopsy have not been quantified. Our objective was to determine risk factors for end-stage kidney disease (ESKD) in patients with glomerulonephritis and crescents on kidney biopsy. A query of the Pediatric Nephrology Research Consortium’s Pediatric Glomerulonephritis with Crescents registry identified 305 patients from 15 centers. A retrospective cohort study was performed with ESKD as the primary outcome. Median age at biopsy was 11 years (range 1–21). The percentage of crescents was 3–100% (median 20%). Etiologies included IgA nephropathy (23%), lupus (21%), IgA vasculitis (19%) and ANCA-associated GN (13%), post-infectious GN (5%), and anti-glomerular basement membrane disease (3%). The prevalence of ESKD was 12% at one year and 16% at last follow-up (median = 3 years, range 1–11). Median time to ESKD was 100 days. Risk factors for ESKD included %crescents, presence of fibrous crescents, estimated GFR, and hypertension at biopsy. For each 1% increase in %crescents, there was a 3% decrease in log odds of 1-year renal survival (p = 0.003) and a 2% decrease in log odds of renal survival at last follow-up (p < 0.001). These findings provide an evidence base for enrollment criteria for crescentic glomerulonephritis in future clinical trials.
Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database
Achilli, Pietro , Mathis, Kellie L. , D’Angelo, Anne-Lise D. , Aziz, Mohamed A. Abd El , Day, Courtney N. , Harmsen, William S. , Crippa, Jacopo , D'Angelo, Anne-Lise D, Abd El Aziz, Mohamed A, Achilli, P , Abd El Aziz, Mohamed A , Grass, Fabian , Larson, David W.

Mayo Clinic

International Journal of Cancer | July 8, 2020 | Volume: 148 | Issue: 1 | Pages: 161-169

10.1002/ijc.33203 | PMID 32638371 Get It

AbstractUtility of adjuvant chemotherapy for stage II cancer remains a matter of debate. Clinical guidelines suggest adjuvant chemotherapy for stage II tumors with high‐risk features, in particular T4 tumors. However, limited consensus exists regarding the importance of other high‐risk features (lymphovascular or perineural invasion, microsatellite instability). Our study aimed to investigate the impact of adjuvant chemotherapy for stage IIA (T3N0) colon cancer patients. Patients who underwent colectomy for stage IIA colon adenocarcinoma (2010‐2015) were identified in the National Cancer Database (NCDB) and divided in two groups based on receipt of adjuvant chemotherapy vs observation. Inverse probability of treatment weighting (IPTW)‐adjusted Kaplan‐Meier and Cox proportional hazards regression analyses were performed to compare overall survival between the two groups. Subgroup analysis of patients with specific high‐risk features LVI, PNI and MSI was performed. Among 46 688 surgical patients with stage IIA colon adenocarcinoma 5937 (12.7%) received adjuvant chemotherapy, while 40 751 (87.3%) were observed. Five‐year IPTW‐adjusted survival was higher in the adjuvant chemotherapy group (79.7% [95% CI 79.1, 80.2]) compared to the observation group (70.3% [95% CI 69.7, 70.9]). Patients with high‐risk pathological features showed an estimated 5‐year survival benefit of 11.3% (78.2% [95% CI 77.4, 79.1] vs 66.9% [95% CI 65.9, 67.8]) when treated with adjuvant chemotherapy. This NCDB analysis revealed a survival benefit for patients with stage IIA colon adenocarcinoma and high‐risk features that were treated with adjuvant chemotherapy.
Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Sylte, Dillon O , Henry, Nathaniel J , LeGrand, Kate E , Abdelalim, Ahmed , Abdulkader, Rizwan Suliankatchi , Abedi, Aidin , Eshete, Akine , Abushouk, Abdelrahman Ibrahim , Adebayo, Oladimeji , Agudelo‐Botero, Marcela , Ahmad, Tauseef , Aichour, Miloud Taki Eddine, Alahdab, Fares , Alamene, Genet Melak, Alanezi, Fahad , Alebel, Animut , Alema, Niguse Meles , Ali, Beriwan Abdulqadir, Alikhani, Mahtab , Alipour, Vahid, Almasri, Nihad A. , Altirkawi, Khalid A , Amer, Yasser Sami , Amini, Saeed, Amit, Arianna Maever L. , Andrei, Cătălina Liliana , Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Ariani, Filippo , Arora, Amit , Asghari, Babak , Awoke, Nefsu , Quintanilla, Beatriz Paulina Ayala , Ayano, Getinet , Ayanore, Martin Amogre , Azari, Samad , Azarian, Ghasem , Badawi, Alaa, Badiye, Ashish , Bagli, Eleni , Baig, Atif Amin , Bairwa, Mohan , Bakhtiari, Ahad , Banach, Maciej , Banerjee, Srikanta , Banik, Palash Chandra , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Barrero, Lope H. , Barzegar, Akbar , Baye, Bayisa Abdissa , Bekuma, Tariku Tesfaye , Belete, Habte , Bennett, Derrick , Berhe, Kidanemaryam , Bhardwaj, Pankaj , Bhat, Anusha Ganapati , Bhattacharyya, Krittika , Bijani, Ali , Sayeed, Muhammad Shahdaat Bin , Borzì, Antonio Maria , Bražinová, Alexandra, Брико, Н. И. , Budhathoki, Shyam Sundar , Car, Josip , Cárdenas, Rosario , Carvalho, Félix , Castaldelli-Maia, João Maurício , Castañeda-Orjuela, Carlos A , Castelpietra, Giulio , Catalá-López, Ferrán , Cerin, Ester , Chandan, Joht Singh , Chanie, Wagaye Fentahun, Chattu, Soosanna Kumary , Chattu, Vijay Kumar , Chaudhary, Neha , Cho, Daniel , Chowdhury, Mohiuddin Ahsanul Kabir , Chu, Dinh‐Toi , Colquhoun, Samantha , Costa, Vera Marisa , Damiani, Giovanni , Dávila-Cervantes, Claudio Alberto , Demoz, Gebre Teklemariam , Demsie, Desalegn Getnet , Derakhshani, Afshin , Deribe, Kebede , Desai, Rupak , Nasab, Mostafa Dianati, Silva, Diana Dias da , Forooshani, Zahra Sadat Dibaji, Doyle, Kerrie , Driscoll, Tim , Dubljanin, Eleonora , Adema, Bereket Duko , Eagan, Arielle Wilder , Eftekhari, Aziz , Ehsani‐Chimeh, Elham , Elemineh, Demelash Abewa , El-Jaafary, Shaimaa I , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Emamian, Mohammad Hassan , Endalew, Daniel Adane , Faris, Pawan , Faro, André , Farzadfar, Farshad , Fatahi, Yousef , Fekadu, Wubalem , Ferede, Tomas Y, Fereshtehnejad, Seyed‐Mohammad , Fernandes, Eduarda , Ferrara, Pietro , Feyissa, Garumma Tolu , Fischer, Florian , Foláyan, Morẹ́nikẹ́ Oluwátóyìn , Francis, Joel M , Fukumoto, Takeshi , Geberemariyam, Biniyam Sahiledengle, Gebre, Abadi Kahsu , Gebremedhin, Ketema Bizuwork , Gebremeskel, Gebreamlak Gebremedhn , Gebremichael, Berhe , Gedefaw, Getnet , Geta, Birhanu, Ghafourifard, Mansour , Ghamari, Farhad , Ghashghaee, Ahmad , Gholamian, Asadollah , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Gubari, Mohammed Ibrahim Mohialdeen , Guo, Yuming , Haagsma, Juanita A. , Hafezi‐Nejad, Nima , Hall, Brian J. , Hamadeh, Randah R , Hasan, Md. Mehedi , Hassen, Hamid Yimam , Havmoeller, Rasmus, Heydarpour, Fatemeh , Hı́jar, Martha , Ho, Hung Chak , Hoang, Chi Linh , Hole, Michael K., Hossain, Naznin , Hosseinzadeh, Mehdi , Hostiuc, Sorin , Ibitoye, Segun Emmanuel , Ilić, Irena , Ilić, Milena , Inbaraj, Leeberk Raja , Indriasih, Endang , Irvani, Seyed Sina Naghibi , Islam, Sheikh Mohammed Shariful , Islam, M. Mofizul , Ivers, Rebecca , Jacobsen, Kathryn H. , Jahani, Mohammad Ali, Jahanmehr, Nader , Jakovljević, Mihajlo , Jayaraman, Sudha , Jha, Ravi Prakash , John-Akinola, Yetunde O. , Joseph, Nitin , Joukar, Farahnaz, Jozwiak, Jacek Jerzy , Jürisson, Mikk , Kadel, Rajendra , Kahsay, Amaha , Kalankesh, Leila R , Kalhor, Rohollah , Kamil, Teshome Abegaz, Kapoor, Neeti , Karami, Manoochehr , Kasaeian, Amir , Kassaye, Hagazi Gebremedhin, Kavetskyy, Taras , Kebede, Hafte Kahsay , Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Kelkay, Bayew, Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khalil, Ibrahim A, Khalilov, Rovshan , Khan, Ejaz Ahmad , Khan, Maseer , Khanna, Tripti, Shadmani, Fatemeh Khosravi , Khundkar, Roba , Kiirithio, Daniel N, Kim, Yun Jin , Kısa, Adnan , Kısa, Sezer , Komaki, Hamidreza , Kondlahalli, Shivakumar K M, Korshunov, Vladimir Andreevich , Kraemer, Moritz U. G. , Krishan, Kewal , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Vivek , Kumar, G Anil , Kumar, Manasi , Kumaresh, Girikumar, Kurmi, Om , Kuti, Oluwatosin, Lami, Faris , Lamichhane, Prabhat , Lang, Justin J. , Lasrado, Savita , Leasher, Janet L , Lee, Shaun Wen Huey , Lenjebo, Tsegaye Lolaso , Li, Shanshan , Linn, Shai , Liu, Xuefeng , Lunevičius, Raimundas , Lyons, Ronan A , Madadin, Mohammed , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Malagón-Rojas, Jeadran , Maled, Venkatesh , Manafi, Navid , Manafi, Amir , Manda, Ana-Laura, Mansour-Ghanaei, Fariborz, Mansouri, Borhan , March, Lyn , Mason‐Jones, Amanda J. , Masoumi, Seyedeh Zahra , Massenburg, Benjamin B. , Maulik, Pallab K , Meles, Gebrekiros Gebremichael , Melketsedik, Zeleke Aschalew , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Merie, Hayimro Edemealem , Miazgowski, Bartosz , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Mirzaei-Alavijeh, Mehdi , Mithra, Prasanna , Moazen, Babak , Moghadaszadeh, Masoud, Mohammad, Yousef , Mohammad, Karzan Abdulmuhsin , Mezerji, Naser Mohammad Gholi, Mohammadian-Hafshejani, Abdollah , Mohammadoo-Khorasani, Milad, Mohammed, Shafiu , Mohammed, Jemal , Mohebi, Farnam , Molokhia, Mariam , Monasta, Lorenzo , Moodley, Yoshan , Moosazadeh, Mahmood , Moradi, Masoud , Moradi, Ghobad , Moradpour, Farhad , Morawska, Lídia , Velásquez, Ilais Moreno , Mossie, Tilahun Belete , Murthy, Srinivas , Musa, Kamarul Imran , Mustafa, Ghulam , Nabhan, Ashraf , Nagarajan, Ahamarshan Jayaraman , Naik, Gurudatta , Naimzada, Mukhammad David , Nangia, Vinay, Nascimento, Bruno Ramos , Naserbakht, Morteza , Ndwandwe, Duduzile , Negoi, Ionuţ , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nikbakhsh, Rajan , Ningrum, Dina Nur Anggraini , Nnaji, Chukwudi A , Nyasulu, Peter S. , Ogbo, Felix Akpojene , Oghenetega, Onome Bright , Okunga, Emmanuel , Olagunju, Andrew T , Olagunju, Tinuke O , Bali, Ahmed Omar , Onwujekwe, Obinna , Asante, Kwaku Oppong , Orpana, Heather , Otstavnov, Nikita , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakshir, Keyvan , Panda‐Jonas, Songhomitra, Park, Eun‐Kee , Patel, Sangram Kishor , Pathak, Ashish , Pati, Sanghamitra , Paulos, Kebreab , Pepito, Veincent Christian Filipino , Pham, Hai Quang , Pinheiro, Marina , Полибин, Р. В. , Polinder, Suzanne, Poustchi, Hossein, Prakash, Swayam , Pribadi, Dimas Ria Angga , Puri, Parul , Syed, Zahiruddin Quazi, Rabiee, Navid , Radfar, Amir , Rafay, Anwar, Rafiee, Ata , Rafiei, Alireza , Rahim, Fakher , Rahimi, Siavash , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Rajabpour-Sanati, Ali, Rajati, Fatemeh , Rakovac, Ivo , Ranganathan, Kavitha , Rao, Sowmya J, Rashedi, Vahid , Rastogi, Prateek , Rathi, Priya , Rawal, Lal , Rawassizadeh, Reza , Renjith, Vishnu , Renzaho, André M. N. , Resnikoff, Serge , Rezapour, Aziz, Rickard, Jennifer , Ríos-González, Carlos Miguel , Sabde, Yogesh , Saddik, Basema , Safari, Saeed , Safarpour, Hamid , Safdarian, Mahdi , Sajadi, S. Mohammad , Salamati, Payman, Salehi, Farkhonde , Zahabi, Saleh Salehi , Salem, Marwa Rashad , Salem, Hosni , Salman, Omar , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Santric-Milicevic, Milena M , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Sawyer, Susan M. , Saxena, Sonia , Schwebel, David C. , Seedat, Soraya , Senthilkumaran, Subramanian , Seyedmousavi, Seyedmojtaba , Sha, Feng , Shaahmadi, Faramarz , Shaikh, Masood Ali , Shams-Beyranvand, Mehran , Shamsizadeh, Morteza , Sharif-Alhoseini, Mahdi , Sharifi, Hamid , Sheikh, Aziz , Shigematsu, Mika, Shin, Jae Il , Shiri, Rahman , Sigfúsdóttir, Inga Dóra, Singh, Pankaj Kumar , Sinha, Dhirendra Narain , Smarandache, Catalin-Gabriel , Soleymani, Bija, Soriano, Joan B. , Soyiri, Ireneous N , Stein, Dan J. , Sufiyan, Mu’awiyyah Babale , Suleria, Hafiz Ansar Rasul , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Wogayehu, Biruk , Tamiru, Animut Tagele , Tarigan, Ingan Ukur , Tefera, Yibekal Manaye , Tekle, Merhawi Gebremedhin , Tekulu, Gebretsadkan Hintsa , Kassie, Ayenew , Bedaso, Asres , Tlaye, Kenean Getaneh , Tohidinik, Hamid Reza , Topór-Mądry, Roman , Tripathy, Jaya Prasad , Tsai, Alexander C. , Car, Lorainne Tudor , Ullah, Saif , Ullah, Irfan , Umar, Maida, Unnikrishnan, Bhaskaran , Upadhyay, Era , Valdéz, Pascual , Violante, Francesco Saverio , Waheed, Yasir , Teklay, Girmay , Werdecker, Andrea , Wiangkham, Taweewat , Wolde, Haileab Fekadu , Woldeyes, Dawit Habte , Yadav, Rajaram , Yadollahpour, Ali , Yano, Yuichiro , Yaya, Sanni , Yazdi‐Feyzabadi, Vahid , Yisma, Engida , Yoon, Seok‐Jun , Youm, Yoosik , Younis, Mustafa Z , Yousefi, Zabihollah , Yu, Yong , Yusefzadeh, Hasan, Moghadam, Telma Zahirian , Zaman, Sojib Bin , Zamanian, Maryam , Zhang, Zhi-Jiang , Zhang, Yunquan , Zodpey, Sanjay , Dandona, Lalit , Dandona, Rakhi , Hay, Simon I , Mokdad, Ali H. , Reiner, Robert C. , Sartorius, Benn , Vos, Theo , Topór‐Mądry, Roman , Zahiruddin, Quazi Syed , Dianatinasab, Mostafa , Sanati, Ali Rajabpour , Baig, Atif Amin , Kumar, Vivek , Stein, Dan J , Castaldelli-Maia, João M , Farzadfar, Farshad , Shin, Jae I L , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Belete, T , Liu, Zichen, Roberts, Nicholas L S , Abdoli, Amir , Abdollahpour, Ibrahim , Ahmed, Rushdiá , Ahmed, Muktar Beshir , Alghnam, Suliman Abdullah , Al‐Hajj, Samar , Ali, Saqib , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Amini, Saeed, Antonio, Carl Abelardo T. , Arab-Zozani, Morteza , Asaad, Malke , Balachandran, Arun , Bayati, Mohsen , Bedi, Neeraj , Behzadifar, Masoud , Benjet, Corina L. , Benseñor, Isabela M. , Bibi, Sadia , Borges, Guilherme , Boufous, Soufiane , Chatziralli, Irini , Constantin, María Magdalena , Daryani, Ahmad , Demeke, Feleke Mekonnen , Demis, Asmamaw , Forooshani, Zahra Sadat Dibaji, Duko, Bereket , Zaki, Maysaa El Sayed , Adane, Daniel, Eskandarieh, Sharareh , Yeheyis, Tomas Y. , Filip, Irina , Foroutan, Masoud , Franklin, Richard C. , Gill, Tiffany K. , Grivna, Michal , Guimarães, Rafael Alves , Gupta, Gaurav Kumar , Haghparast‐Bidgoli, Hassan , Hamidi, Samer , Haro, Josep María , Hasanzadeh, Amir , Hassanipour, Soheil , Hassankhani, Hadi , Hayat, Khezar , Hendrie, Delia V. , Holla, Ramesh , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jalilian, Farzad , Jayatilleke, Achala Upendra , Jonas, Jost B , Jungari, Suresh Banayya , Kabir, Ali , Kanchan, Tanuj , Rade, Bayew Kelkay , Khalil, Ibrahim A, Khammarnia, Mohammad , Khazaie, Habibolah , Kim, Young‐Eun , Kim, Daniel , Shivakumar, KM , Koyanagi, Ai , Kumar, Nithin , Vecchia, Carlo La , Lansingh, Van Charles , Laryea, Dennis Odai , Latifi, Arman , Lauriola, Paolo , Levi, Miriam , Lopez, Alan D , Lotufo, Paulo A. , Majeed, Azeem , Malekzadeh, Reza , Malta, Déborah Carvalho , Manjunatha, Narayana , Mansour‐Ghanaei, Fariborz , Mansournia, Mohammad Alì , Maravilla, Joemer Calderon , Melese, Addisu Dagnaw , Aschalew, Zeleke , Mengesha, Meresa Berwo , Meštrović, Tomislav , Mirică, Andreea , Mohamadi, Efat , Darwesh, Aso Mohammad , Mohammadpourhodki, Reza , Moradi‐Lakeh, Maziar , Morisaki, Naho , Morrison, Shane D. , Muluneh, Atalay Goshu , Najafi, Farid , Nayak, Vinod C , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Ota, Erika , Patton, George , Peden, Amy E. , Pereira, Jeevan , Phillips, Michael , Rabiee, Mohammad , Rawaf, Salman , Ribeiro, Ana Isabel , Ronfani, Luca , Roshandel, Gholamreza , Saad, Anas M. , Sabour, Siamak , Safari‐Faramani, Roya , Salamati, Payman, Sarker, Abdur Razzaque , Sayyah, Mehdi , Sepanlou, Sadaf Ghajarieh , Shahabi, Saeed , Siabani, Soraya , Singh, Jasvinder A. , Smith, Emma U.R. , Soheili, Amin , Soltanian, Ali Reza , Sorrie, Muluken Bekele , Stokes, Mark Andrew , Tadesse, Degena Bahrey , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Thapar, Rekha , Tran, Bach Xuan , Tran, Khanh Bao , Uthman, Olalekan Abdulrahman , Vasankari, Tommi Juhani , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Wondafrash, Dawit Zewdu , Wondmeneh, Temesgen Gebeyehu , Wondmieneh, Adam Belay , Wu, Aimin , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zandian, Hamed , Zarei, Ahmad , Zare, Fatemeh, Degenhardt, Louisa J , Dharmaratne, Samath Dhamminda , Olagunju, Andrew T , Baig, Atif Amin , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

Injury Prevention | April 24, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i96-i114

10.1136/injuryprev-2019-043494 | PMID 32332142 Get It

Background Past research in population health trends has shown that injuries form a substantial burden of population health loss. Regular updates to injury burden assessments are critical. We report Global Burden of Disease (GBD) 2017 Study estimates on morbidity and mortality for all injuries. Methods We reviewed results for injuries from the GBD 2017 study. GBD 2017 measured injury-specific mortality and years of life lost (YLLs) using the Cause of Death Ensemble model. To measure non-fatal injuries, GBD 2017 modelled injury-specific incidence and converted this to prevalence and years lived with disability (YLDs). YLLs and YLDs were summed to calculate disability-adjusted life years (DALYs). Findings In 1990, there were 4 260 493 (4 085 700 to 4 396 138) injury deaths, which increased to 4 484 722 (4 332 010 to 4 585 554) deaths in 2017, while age-standardised mortality decreased from 1079 (1073 to 1086) to 738 (730 to 745) per 100 000. In 1990, there were 354 064 302 (95% uncertainty interval: 338 174 876 to 371 610 802) new cases of injury globally, which increased to 520 710 288 (493 430 247 to 547 988 635) new cases in 2017. During this time, age-standardised incidence decreased non-significantly from 6824 (6534 to 7147) to 6763 (6412 to 7118) per 100 000. Between 1990 and 2017, age-standardised DALYs decreased from 4947 (4655 to 5233) per 100 000 to 3267 (3058 to 3505). Interpretation Injuries are an important cause of health loss globally, though mortality has declined between 1990 and 2017. Future research in injury burden should focus on prevention in high-burden populations, improving data collection and ensuring access to medical care.
The effect of androgen deprivation on mini-mental status examination in patients with biochemical recurrence of prostate cancer
Tan, Winston , Wehle, Michael J., Graff-Radfford, N., Buskirk, Steven J.

Mayo Clinic

Journal of Clinical Oncology | March 6, 2020 | Volume: 25 | Issue: 18_suppl | Pages: 15592-15592

10.1200/jco.2007.25.18_suppl.15592 Get It

15592 Background: Androgen deprivation (AD) is a common treatment option for asymptomatic patients with biochemical recurrence of prostate cancer. Side effects such as sexual dysfunction, hot flashes, fatigue and gynecosmastia have been well documented. However, some of the side effects such as osteoporosis, insulin resistance, hyperglycemia, and anemia have only been recently recognized. The effects of AD on memory are not known. Aim: To determine if there is a decline in cognitive function(CF) in patients on AD using the modified MiniMental Status examination (MMSE). This test was chosen because it was simple, easy to administer and reproducible. Methods: We prospectively enrolled men with biochemical recurrence of prostate cancer prior to initiation of AD and monitored their MMSE at baseline, 2 ,and 4 months and while on AD (Mayo Clinic Jacksonville 8/2004- 9/2006). Results: 38 men were enrolled,however, only 20 men had at least 3 MMSE testing done. (5 withdrew consent, 13 had missing MMSE or lost to followup). The mean age was 68 years, mean baseline MMSE score was 27 and none had a clinical diagnosis of dementia or depression. Comparing the first MMSE and the 2nd MMSE score 19/20 patients had no decline of CF except for one patient who had a transient decline of 5 points in his MMSE score during a period of depression ,however, he had subsequent recovery of his score back to his normal baseline 27. Comparing the first and third MMSE score 20/20 patients had no decline of CF. The mean score change in MMSE score was -1 in 3 patients, 0 in 9 patients, +1 in 4 patients, +2 in 2 patients and +3 in 2 patients. There was no decline of 3 or more points in the mean score in any patient. Interestingly, 2 patients had an 3 point improvement of their MMSE score. We felt that it was secondary to being more familiar to the test process and not due to AD. Conclusions: There is no significant decline in MMSE score in men on AD at 2 and 4 months. MMSE might not be able to detect subtle changes in memory therefore, further study with more sensitive test to discriminate CF decline would be warranted and with longer followup cognitive impairement may be more evident. No significant financial relationships to disclose.
Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials
Shi, Qian , Taı̈eb, Julien , Meyers, Jeffrey P., Smyrk, Thomas C. , Julié, Catherine , Zawadi, Ayman, Mini, Enrico , Goldberg, Richard M. , Folprecht, Gunnar , Laethem, Jean‐Luc Van , Malicot, Karine Le , Laurent‐Puig, Pierre , Zaanan, Aziz , Shi, Qian , Taieb, Julien , Laurent-Puig, Pierre , Alberts, Steven R. , Tabernero, Josep , Sargent, Daniel J. , Sinicrope, Frank A.

Mayo Clinic

JCO Precision Oncology | February 26, 2020 | Volume: No volume available | Issue: 4 | Pages: 116-127

10.1200/po.19.00237 | PMID 32923882 Get It

PURPOSE The microsatellite instability (MSI) or deficient mismatch repair (dMMR) phenotype is usually regarded as a single biologic entity, given the absence of comparative analyses regarding prognosis and response to chemotherapy between sporadic and familial dMMR cancers. PATIENTS AND METHODS Patients with stage III colon cancers were randomly assigned to FOLFOX (leucovorin, fluorouracil, and oxaliplatin) with or without cetuximab in 2 large adjuvant phase III trials (N = 5,577). Among patients with MSI and KRAS exon 2 wild-type (WT) tumors, the prognostic and predictive impacts of sporadic versus familial dMMR cancers and BRAF V600E mutational status were determined. Multivariable Cox proportional hazards models were used to assess disease-free survival (DFS) by treatment arm, adjusting for age, sex, tumor grade, Eastern Cooperative Oncology Group performance status, pT/pN stage, and primary tumor location. RESULTS Among patients with MSI status with complete data for dMMR mechanism analysis (n = 354), 255 (72%) had sporadic ( BRAF mutation and/or MLH1 methylation) and 99 (28%) had familial tumors ( BRAF WT and unmethylated MLH1 or loss of MSH2/MSH6/PMS2 protein expression). A large proportion of dMMR sporadic tumors were mutated for BRAF (n = 200). In patients treated with FOLFOX, DFS did not differ statistically by dMMR mechanism, whereas in patients treated with FOLFOX plus cetuximab, those with sporadic tumors had worse DFS than those with familial cancers (multivariable hazard ratio, 2.69; 95% CI, 1.02 to 7.08; P = .04). Considering the predictive utility, the interaction between treatment and dMMR mechanism was significant ( P = .03). Furthermore, a nonsignificant trend toward a deleterious effect of adding cetuximab to FOLFOX was observed in patients with BRAF-mutant but not BRAF WT tumors. CONCLUSION The addition of cetuximab to adjuvant FOLFOX was associated with shorter DFS in patients with sporadic dMMR colon cancer. Additional studies are needed to validate these results in metastatic disease.
Risk factors for conversion in laparoscopic and robotic rectal cancer surgery
Crippa, Jacopo , Achilli, Pietro , Mathis, Kellie L. , Merchea, Amit , Crippa, J , Grass, F , Achilli, P , Grass, Fabian , Kelley, Scott R. , Colibaseanu, Dorin , Larson, David W.

Mayo Clinic

British Journal of Surgery | January 24, 2020 | Volume: 107 | Issue: 5 | Pages: 560-566

10.1002/bjs.11435 | PMID 31976558 Get It

Abstract Background The aim of this study was to review risk factors for conversion in a cohort of patients with rectal cancer undergoing minimally invasive abdominal surgery. Methods A retrospective analysis was performed of consecutive patients operated on from February 2005 to April 2018. Adult patients undergoing low anterior resection or abdominoperineal resection for primary rectal adenocarcinoma by a minimally invasive approach were included. Exclusion criteria were lack of research authorization, stage IV or recurrent rectal cancer, and emergency surgery. Risk factors for conversion were investigated using logistic regression. A subgroup analysis of obese patients (BMI 30 kg/m2 or more) was performed. Results A total of 600 patients were included in the analysis. The overall conversion rate was 9·2 per cent. Multivariable analysis showed a 72 per cent lower risk of conversion when patients had robotic surgery (odds ratio (OR) 0·28, 95 per cent c.i. 0·15 to 0·52). Obese patients experienced a threefold higher risk of conversion compared with non-obese patients (47 versus 24·4 per cent respectively; P &lt; 0·001). Robotic surgery was associated with a reduced risk of conversion in obese patients (OR 0·22, 0·07 to 0·71). Conclusion Robotic surgery was associated with a lower risk of conversion in patients undergoing minimally invasive rectal cancer surgery, in both obese and non-obese patients.
Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017
Haagsma, Juanita A. , James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Lucchesi, Lydia R , Sylte, Dillon O , Adebayo, Oladimeji , Ahmadi, Alireza , Aichour, Miloud Taki Eddine, Alahdab, Fares , Al‐Raddadi, Rajaa , Alsharif, Ubai , Altirkawi, Khalid A , Anjomshoa, Mina, Appiah, Seth Christopher Yaw , Aremu, Olatunde , Arora, Amit , Assadi, Reza , Awasthi, Ashish , Quintanilla, Beatriz Paulina Ayala , Balalla, Shivanthi , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Behzadifar, Meysam, Bennett, Derrick , Bhaumik, Soumyadeep , Bhutta, Zulfiqar A , Bijani, Ali , Borges, Guilherme , Borschmann, Rohan , Bose, Dipan, Bražinová, Alexandra, Campuzano, Julio César , Cárdenas, Rosario , Carvalho, Félix , Castañeda-Orjuela, Carlos A , Catalá-López, Ferrán , Choi, Jee-Young Jasmine , Christopher, Devasahayam Jesudas , Crowe, Christopher S. , Dalal, Koustuv , Leo, Diego De, Neve, Jan‐Walter De , Deribe, Kebede , Dessie, Getenet , deVeber, Gabrielle , Dharmaratne, Samath Dhamminda , Doan, Linh Phuong , Driscoll, Tim , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Endries, Aman Yesuf , Faro, André , Fereshtehnejad, Seyed‐Mohammad , Fernandes, Eduarda , Fischer, Florian , Franklin, Richard C. , Fukumoto, Takeshi , Gezae, Kebede Embaye , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Guo, Yuming , Haghparast‐Bidgoli, Hassan , Haj‐Mirzaian, Arvin , Haj‐Mirzaian, Arya , Hamadeh, Randah R , Hassen, Hamid Yimam , Havmoeller, Rasmus, Henok, Andualem , Hı́jar, Martha, Hole, Michael K., Rad, Enayatollah Homaie , Hossain, Naznin , Hostiuc, Sorin , Igumbor, Ehimario , Irvani, Seyed Sina Naghibi , Islam, Sheikh Mohammed Shariful , Ivers, Rebecca , Jacobsen, Kathryn H. , Jahanmehr, Nader , Jakovljević, Mihajlo , Jha, Ravi Prakash , Shushtari, Zahra Jorjoran , Jozwiak, Jacek Jerzy , Jürisson, Mikk , Kalani, Rizwan, Kasaeian, Amir , Kelbore, Abraham Getachew , Kengne, André Pascal , Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khan, Ejaz Ahmad , Kiadaliri, Ali , Kim, Yun Jin , Kısa, Adnan , Defo, Barthélémy Kuate , Biçer, Burcu Küçük , Kumar, Manasi , Lalloo, Ratilal , Lam, Hilton Y. , Lami, Faris , Leasher, Janet L , Li, Shanshan , Linn, Shai , Lunevičius, Raimundas , Machado, Flávia Ribeiro , Razek, Hassan Magdy Abd El , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Majeed, Azeem , Malekzadeh, Reza, Malik, Manzoor Ahmad , Manda, Ana-Laura, Massenburg, Benjamin B. , Maulik, Pallab K , Meheretu, Hailemariam Abiy Alemu , Mehndiratta, Man Mohan, Mendoza, Walter, Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Moazen, Babak , Mezerji, Naser Mohammad Gholi, Mohammadibakhsh, Roghayeh , Mohammed, Shafiu , Molokhia, Mariam , Monasta, Lorenzo , Mondello, Stefania , Montero-Zamora, Pablo A. , Moodley, Yoshan , Moosazadeh, Mahmood , Moradi, Ghobad , Morawska, Lídia , Velásquez, Ilais Moreno , Moschos, Marilita M. , Mousavi, Seyyed Meysam , Murthy, Srinivas , Musa, Kamarul Imran , Naik, Gurudatta , Nangia, Vinay, Nascimento, Bruno Ramos , Ndwandwe, Duduzile , Negoi, Ionuţ , Nguyen, Son Hoang , Nguyen, Long Hoang , Ningrum, Dina Nur Anggraini , Nirayo, Yirga Legesse, Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Oladimeji, Olanrewaju , Olagunju, Andrew T , Olagunju, Tinuke O , Orpana, Heather , Otstavnov, Stanislav S , Mahesh, P A , Pakhalé, Smita , Park, Eun‐Kee , Pesudovs, Konrad , Polinder, Suzanne , Prakash, Swayam , Rafay, Anwar, Rafiei, Alireza , Rahimi, Siavash , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Kumar, Rajesh , Ramezanzadeh, Kiana, Rawaf, David Laith , Renzaho, André M. N. , Resnikoff, Serge , Roever, Leonardo , Sabde, Yogesh , Saddik, Basema , Salamati, Payman , Salimi, Yahya , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Santric-Milicevic, Milena M , Satpathy, Maheswar , Sawhney, Monika, Sawyer, Susan M. , Şaylan, Mete , Schwebel, David C. , Seedat, Soraya , Shaikh, Masood Ali, Shams-Beyranvand, Mehran , Shamsizadeh, Morteza , Sharif-Alhoseini, Mahdi , Sheikh, Aziz , Shigematsu, Mika, Shiri, Rahman , Shiue, Ivy , Silva, João Pedro , Sinha, Dhirendra Narain , Filho, Adauto Martins Soares , Soriano, Joan B. , Soshnikov, Sergey , Soyiri, Ireneous N , Starodubov, Vladimir I., Stein, Dan J. , Sufiyan, Mu’awiyyah Babale , Sunshine, Jacob E. , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Tessema, Gizachew Assefa , Thakur, Jarnail Singh , Car, Lorainne Tudor , Uzochukwu, Benjamin, Valdéz, Pascual , Varavikova, Elena A. , Vasconcelos, Ana Maria Nogales , Violante, Francesco Saverio , Waheed, Yasir , Wang, Yuan‐Pang , Wijeratne, Tissa , Yadav, Priyanka , Yano, Yuichiro , Yenesew, Muluken Azage, Yisma, Engida , Younis, Mustafa Z , Zafar, Shamsa , Zaman, Sojib Bin , Zodpey, Sanjay , Hay, Simon I , Mokdad, Ali H. , Vos, Theo , Khubchandani, Jagdish , Padrón‐Monedero, Alicia , Wijeratne, T , Stein, Dan J , Islam, Sheikh Mohammed Shariful , Assadi, Reza , Rahman, Muhammad Aziz , Liu, Zichen, Roberts, Nicholas L S , Ahmed, Muktar Beshir , Alghnam, Suliman Abdullah , Aljunid, Syed Mohamed , Antonio, Carl Abelardo T. , Asayesh, Hamid , Bazargan‐Hejazi, Shahrzad , Bedi, Neeraj , Behzadifar, Masoud , Behzadifar, Meysam, Benjet, Corina L. , Benseñor, Isabela M. , Boufous, Soufiane , Carrero, Juan Jesús , Daryani, Ahmad , Daviţoiu, Dragoş Virgil , Degenhardt, Louisa J , Dolan, Kate A , Dubey, Manisha , Zaki, Maysaa El Sayed , Eskandarieh, Sharareh , Filip, Irina , Gill, Tiffany K. , Gupta, Rahul, Hamidi, Samer , Haro, Josep María , Hassankhani, Hadi , Hendrie, Delia V. , Hı́jar, Martha , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jayatilleke, Achala Upendra , Jonas, Jost B , Kabir, Ali , Kalani, Rizwan, Khoja, Abdullah T , Kim, Young‐Eun , Kim, Daniel , Koyanagi, Ai , Lansingh, Van Charles , Malta, Déborah Carvalho , Mansournia, Mohammad Alì , Melese, Addisu Dagnaw , Meštrović, Tomislav , Moradi‐Lakeh, Maziar , Morrison, Shane D. , Najafi, Farid , Nguyen, Trang Huyen , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Olivares, Pedro Rufino , Patton, George , Phillips, Michael , Radfar, Amir , Rawaf, Salman , Rezaeian, Shahab , Ronfani, Luca , Roshandel, Gholamreza , Saxena, Sonia , Schneider, Ione Jayce Ceola , Sepanlou, Sadaf Ghajarieh , Shen, Jiabin , Singh, Jasvinder A. , Стародубов, В. И. , Stokes, Mark Andrew , Tehrani‐Banihashemi, Arash , Tran, Khanh Bao , Tran, Bach Xuan , Uthman, Olalekan Abdulrahman , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Winkler, Andrea Sylvia , Azage, Muluken , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zhao, Yong , Lopez, Alan D , Olagunju, Andrew T , Alahdab, Fares

Mayo Clinic

Injury Prevention | January 9, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i12-i26

10.1136/injuryprev-2019-043296 | PMID 31915273 Get It

Background The epidemiological transition of non-communicable diseases replacing infectious diseases as the main contributors to disease burden has been well documented in global health literature. Less focus, however, has been given to the relationship between sociodemographic changes and injury. The aim of this study was to examine the association between disability-adjusted life years (DALYs) from injury for 195 countries and territories at different levels along the development spectrum between 1990 and 2017 based on the Global Burden of Disease (GBD) 2017 estimates. Methods Injury mortality was estimated using the GBD mortality database, corrections for garbage coding and CODEm—the cause of death ensemble modelling tool. Morbidity estimation was based on surveys and inpatient and outpatient data sets for 30 cause-of-injury with 47 nature-of-injury categories each. The Socio-demographic Index (SDI) is a composite indicator that includes lagged income per capita, average educational attainment over age 15 years and total fertility rate. Results For many causes of injury, age-standardised DALY rates declined with increasing SDI, although road injury, interpersonal violence and self-harm did not follow this pattern. Particularly for self-harm opposing patterns were observed in regions with similar SDI levels. For road injuries, this effect was less pronounced. Conclusions The overall global pattern is that of declining injury burden with increasing SDI. However, not all injuries follow this pattern, which suggests multiple underlying mechanisms influencing injury DALYs. There is a need for a detailed understanding of these patterns to help to inform national and global efforts to address injury-related health outcomes across the development spectrum.
A Phase II Trial of Autologous Stem Cell Transplant (AHSCT) Followed by Mini-Allogeneic Stem Cell Transplant (AlloTx) for the Treatment of Multiple Myeloma: Analysis of ECOG E4A98.
Vesole, David H. , Zhang, Lijun , Flomenberg, Neal , Greipp, Philip R., Lazarus, Hillard M.

Mayo Clinic

Blood | October 13, 2019 | Volume: 110 | Issue: 11 | Pages: 3027-3027

10.1182/blood.v110.11.3027.3027 Get It

Abstract Background: Conventional AlloTx for MM is associated with TRM exceeding 20%. Non-myeloablative AlloTx (NST) utilizes the known graft-vs-myeloma (GVM) effect in an attempt to eradicate minimal residual disease. Preliminary studies of NST in MM demonstrated significant CR and low 100 day post-NST TRM (Badros et al Blood97:2574, 2001). However, even though response rates were high, the vast majority of pts with significant MM disease at the time of transplant, relapsed within the first year. To provide maximal tumor cytoreduction to allow for a subsequent GVM effect, the ECOG designed a Phase II trial of AHSCT for maximal tumor cytoreduction followed by a matched sibling NST to allow for a GVM effect. Methods: The study was designed as a two-stage process based upon early transplant mortality in the first 100 days. Eligibility included pts treated as part of induction therapy or salvage therapy. Chemotherapy responsive disease was not required. Only matched sibling donors were allowed. Pts must have had adequate PS and physiologic organ function. After stem cell mobilization, pts received melphalan 200 mg/m2 with AHSCT. Pts underwent NST 100–182 d post-AHSCT following fludarabine 30 mg/m2 daily × 5 and cyclophosphamide 1 g/m2 for 2 days. GVHD prophylaxis included cyclosporine and corticosteroids. For pts with acute GVHD, Zenapax 1 mg/kg for 5 doses q 3 d was recommended. GM-CSF was incorporated post-AHSCT and NST. The primary endpoints were day 100 TRM, early graft failure, extent of acute GVHD, toxicities, DFS and OS. The study was suspended for 6 mo after the first 19 pts to evaluate early TRM-no early TRM was observed and the study was re-opened. Results: From 5/3/01 to 1/14/05, 32 pts from 10 institutions were enrolled on the study. 23 patients, median age 51 (range 32–64) completed both transplants (28% drop-out rate): 7 (30%) CR (2 in CCR), 11 (48%) PR and 2 (9%) NR and 3 (13%) NE as the best overall response. Of the 32 pts who completed AHSCT, there were 12 grade 4 toxicities pre-NST; 11/23 pts had grade 4 toxicities post-NST. Acute grade III/IV GVHD was observed in 4 (17%); chronic GVHD was observed in 9 pts (39%): 5 limited; 4 extensive resulting in 3 CR (33%), 1 CCR, and 3 PR (33%). 1 pt (4%) had graft-failure. Two pts (8.7%; 95% CI 1.6%, 24.9%) had TRM prior to day + 100 post-NST. With a median follow up of 3.5 years from registration, the median PFS was 4.4 years and the 2-year survival rate was 78% (95% CI: 61% ∼ 95%) for the 23 pts who completed both transplants. Conclusions: AHSCT followed by NST is feasible in a Cooperative Group setting with a low early TRM. The PFS and OS were superior to historical reports for single and tandem AHSCT. AHSCT-NST tandem transplants resulted in a 78% overall response, including 30% CR (2/7 CCR) - similar to other reports for AHSCT-NST. 3/9 pts with chronic GVHD achieved CR demonstrating the GVM effect. However, a plateau in PFS or OS was not observed indicating that the GVM effect is not sufficient to produce long- term disease control and is unlikely curative using this treatment schema. Future studies should include novel therapies to induce better responses pre-transplant and consideration for post-NST maintenance to further eradicate MRD while allowing for GVM.
Return to Duty After Mini‐Open Arthroscopic‐Assisted Treatment of Femoroacetabular Impingement in an Active Military Population
Song, Daniel J. , Lee, Gregory Y., Tokish, John M. , Ernat, Justin J. , Cage, J. Matthew

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | September 4, 2019 | Volume: 1 | Issue: 1 | Pages: No page available

10.1016/j.asmr.2019.07.003 | PMID 32267252 Get It

Purpose To report the return‐to‐duty rate and surgical outcomes in a military population after mini‐open arthroscopic‐assisted surgery for femoroacetabular impingement (FAI) in an effort to affirm its efficacy. Methods A retrospective review of consecutive active‐duty patients receiving mini‐open arthroscopic‐assisted surgery for FAI between 2007 and 2011 was performed. Patients younger than 18 years, non–active‐duty patients, and patients with prior hip surgery were excluded. Demographic, radiographic, and duty‐status data were collected. The primary outcome measure was a return to duty. Outcome scores were obtained in a proportion of the cohort, including the modified Harris Hip Score, Single Assessment Numeric Evaluation score, Western Ontario and McMaster Universities Osteoarthritis Index score, patient satisfaction score, and Veterans RAND 12 (VR‐12) score. All patients had achieved a minimum of 1 year of follow‐up at the time of assessment. All P values for significance were set at .05 or lower. Results Of 182 patients (average age, 30.4 years), 156 (86%) were available for follow‐up with return‐to‐duty data at an average of 2.8 years (range, 1‐6 years). Of the patients, 78% returned to full duty (53%) or returned to duty with restrictions (25%). Outcome scores were available for 101 of 182 patients (55%) with duty rates similar to the total cohort (81% who returned to duty: 58% with no restrictions and 23% with restrictions). Return to duty correlated with improved outcomes compared with those who were medically discharged with respect to the modified Harris Hip Score (68.2 vs 54.5, P < .03), Single Assessment Numeric Evaluation score (48.2 vs 25.3, P < .02), and VR‐12 physical (39.7 vs 33.2, P < .05) and VR‐12 mental (54.5 vs 43.4, P < .005) scores. Conclusions Mini‐open arthroscopic‐assisted surgery for FAI is successful in returning most service members to duty at short‐term follow‐up. Return correlates with improved outcome scores, although previously reported minimally clinical important difference and patient acceptable symptomatic state threshold values were not uniformly achieved. Level of Evidence Level IV, retrospective case series.